Claims for Patent: 8,637,314

Summary for Patent: 8,637,314

Title:	Reverse micelles based on phytosterols and acylglycerols and therapeutic uses thereof
Abstract:	The present invention relates generally to reverse-m ice liar system comprising a hydrosoluble therapeutically active agent. Reverse micelles according to the invention are particularly useful to deliver drugs. The present invention also relates to pharmaceutical composition comprising said reverse micelles and methods for preparing the same.
Inventor(s):	Maurel; Jean-Claude (Castries, FR)
Assignee:	Medesis Pharma SA (Baillargues, FR)
Application Number:	11/718,513
Patent Claims:	1. A reverse-micellar system comprising at least one hydrosoluble therapeutically active ingredient, a phytosterol, an acylglycerol and water, and wherein the hydrosoluble active ingredient is a peptide, a polypeptide, a protein or a nucleic acid. 2. The reverse-micellar system according to claim 1, wherein the aqueous core of less aqueous core of the reverse-micelles is less than or equal to 100 nm in diameter. 3. The reverse-micellar system according to claim 1, wherein the weight ratio W=(water)/(acylglycerol) is less than or equal to about 2.5. 4. The reverse-micellar system according to claim 1, wherein the weight ratio phytosterol/acylglycerol ranges from 0.01 to 1. 5. The reverse-micellar system according to claim 1, wherein the weight ratio phytosterol/acylglycerol is more than or equal to 0.1. 6. The reverse-micellar system according to claim 1, wherein the weight ratio W=(water)/(acylglycerol) is less than or equal to about 1. 7. The reverse-micellar system according to claim 1, wherein the acylglycerol is: ##STR00002## wherein: R.sub.1 is an acyl residue of a linear or branched, saturated or unsaturated fatty acid having between 14 and 24 carbon atoms, a hydrogen atom, or a mono-, di- or tri-galactose or glucose; R.sub.2 is an acyl residue of a linear or branched, saturated or unsaturated fatty acid having between 2 and 18 carbon atoms; R.sub.3 is an acyl residue of a linear or branched, saturated or unsaturated fatty acid having between 14 and 24 carbon atoms, or an hydrogen atom; and the hydrosoluble active ingredient is a peptide, a polypeptide, a protein or a nucleic acid. 8. The reverse-micellar system according to claim 7, wherein at least one of R.sub.1 and R.sub.3, is an acyl residue of oleic acid (C18: 1[cis]-9). 9. The reverse-micellar system according to claim 7, wherein R.sub.2 is an oleic acid residue (oleoyl group), one of its positional isomers with respect to the double bond (cis-6,7,9,11 and 13) or one of its iso-branched isomers. 10. The reverse-micellar system according to claim 7, wherein R.sub.2 is an acetyl group. 11. The reverse-micellar system according to claim 7, wherein R.sub.3 is a hydrogen atom. 12. The reverse-micellar system according to claim 7, wherein the acylglycerol is 1,2-diolein and 1-oleoyl-2-acetyl glycerol. 13. The reverse-micellar system according to claim 1, wherein the phytosterol is sitosterol. 14. A pharmaceutical composition comprising reverse micelles as defined in claim 1 and a pharmaceutically acceptable support. 15. The reverse-micellar system according to claim 5, wherein the weight ratio phytosterol/acylglycerol is from 0.1 to 0.2. 16. The reverse-micellar system according to claim 8, wherein only one of R.sub.1 and R.sub.3 is an acyl residue of oleic acid (C18: 1[cis]-9). 17. The reverse-micellar system according to claim 1, wherein the nucleic acid is DNA or RNA or fragments thereof. 18. The reverse-micellar system according to claim 17, wherein the RNA is RNAi. 19. The reverse-micellar system according to claim 7, wherein the peptide, the polypeptide, the protein or the nucleic acid is insulin, erythropoietin, leptin, growth factors, growth hormone releasing hormones, colony stimulating factors, hydrosoluble hormones, luteinising hormone releasing hormone (LHRH) or analogues thereof, interferons, cytokines, DNA, RNA fragments or plasmids, RNA interference, immunogenic agents, and/or vaccine agents. 20. The reverse-micellar system according to claim 19, wherein the hydrosoluble hormones are parathyroid hormone or fractions or analogues thereof. 21. The reverse-micellar system according to claim 19, wherein the luteinising hormone releasing hormone (LHRH) or analogues thereof are nafarelin, buserelin, or goserelin. 22. The reverse-micellar system according to claim 1, wherein the peptide, the polypeptide, the protein or the nucleic acid is insulin, erythropoietin, leptin, growth factors, growth hormone releasing hormones, colony stimulating factors, hydrosoluble hormones, luteinising hormone releasing hormone (LHRH) or analogues thereof, interferons, cytokines, DNA, RNA fragments or plasmids, RNA interference, immunogenic agents, and/or vaccine agents. 23. The reverse-micellar system according to claim 22, wherein the hydrosoluble hormones are parathyroid hormone or fractions or analogues thereof. 24. The reverse-micellar system according to claim 22, wherein the luteinising hormone releasing hormone (LHRH) or analogues thereof are nafarelin, buserelin, or goserelin.

Details for Patent 8,637,314

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2024-11-02